CPA
REGN icon

Capital Performance Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Performance Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-785
Closed -$607K – 456
2026
Q1 		$607K Buy
785
+114
+17% +$87.3K 0.04% 194
2025
Q4 		$518K Buy
671
+40
+6% +$27.2K 0.04% 208
2025
Q3 		$355K Buy
+631
New +$357K 0.06% 183
2024
Q4 		– Sell
-13
Closed -$13.7K – 2099
2024
Q3 		$13.7K Buy
+13
New +$14.5K ﹤0.01% 717

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Capital Performance Advisors's REGN Position: Q2 2026 in Review

Capital Performance Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 785 shares — an estimated $607K sold.

Capital Performance Advisors first reported a position in REGN in Q3 2024 and held it in 4 quarters. The position peaked at $607K in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capital Performance Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Capital Performance Advisors sold 785 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $607K.
  • Capital Performance Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Capital Performance Advisors's Regeneron Pharmaceuticals position peaked at $607K in Q1 2026.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capital Performance Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.